未知生产厂商
AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.
AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.
AT3022 utilizes the Company’s proprietary PassPort™ Transdermal System, developed to deliver watersoluble small molecules, proteins, carbohydrates and oligonucleotides across the skin. AT3022 is designed to provide a safer and more efficacious alternative to the currently marketed fentanyl patches that can only deliver the highly lipid-soluble base form of fentanyl.
Investigated for use/treatment in pain (acute or chronic).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
